Fortress Biotech Inc. Preferred Stock 9.375% Perpetual is a type of preferred equity issued by Fortress Biotech Inc., a biopharmaceutical company engaged in the development and commercialization of prescription medications and therapeutic products. This financial instrument offers investors a fixed dividend yield of 9.375%, positioning it as a source of steady income. The "perpetual" nature of this preferred stock indicates it has no fixed maturity date, allowing dividends to be paid indefinitely as long as the issuing company remains solvent. Preferred stocks like this one often appeal to investors seeking stable returns, standing ahead of common equity in the capital structure during liquidation. Fortress Biotech operates across various sectors within the biotech industry, significantly impacting pharmaceutical innovation and therapeutic advancements. The preferred stock's distinctive high-dividend appeal underlines its importance in the market for investors prioritizing income over capital appreciation.
Website1111 Kane Concourse
Bay Harbor Islands, FL, 33154
United States
MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The prese
Moby summary of Fortress Biotech, Inc.'s Q2 2026 earnings call
Total net revenue increased 14% to $18.7 million for second quarter of 2026 compared to second quarter of 2025 Partnered programs continue to advance with Crystalys Therapeutics announcing its $130 million Series B financing to support the late-stage global development and commercialization preparation for dotinurad, and royalties generated from the launches of ZYCUBO® and UNLOXCYT™ MIAMI, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biophar
Fortress Biotech: Q2 Earnings Snapshot
Journey Medical reported higher second-quarter revenue and improved profitability, driven by continued prescription growth and improving payer reimbursement for its rosacea treatment Emrosi. Chief Executive Officer Claude Maraoui said the company generated positive EBITDA in the second quarter and
Investors talking about FBIOP also mention
What share of all stock conversation is about FBIOP?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% 0 | 0% +0 | 0% 0 | 0% +0 |
Of the messages about FBIOP that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | — | 50% new | 33.33% -6.67 | 88.48% +17.75 | ||
| Bearish | — | 50% -50 | 66.67% +6.67 | 11.52% -17.75 |
Of the messages about FBIOP that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Macro | — | — | — | 24.08% | ||
| Announcements | — | — | — | 34.27% | ||
| Technical Analysis | — | — | — | 17.14% | ||
| Analysts | — | — | — | 23.43% | ||
| Controversies | — | — | — | 0.22% | ||
| Earnings | — | — | — | 0.87% |
Of the messages about FBIOP, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | 0% | 50% | 61.54% | 23.99% | ||
| Newcomers | 100% | 50% | 38.46% | 76.01% |